Nexalin Technology Files S-1/A Amendment for IPO
Nexalin Technology, Inc. filed an amended Form S-1/A with the SEC on October 8, 2026, updating its IPO registration. The company develops non-invasive neuromodulation devices. This amendment likely addresses SEC comments, updated financials, or underwriting terms—indicating active progress through the review process.
51CFO view：S-1/A amendments often trigger SEC comment letters requiring CFO-led, cross-functional responses within tight deadlines. For medtech firms, this includes justifying FDA regulatory impact on revenue recognition, R&D capitalization policy under ASC 730, and intercompany cost allocations—all demanding both industry fluency and SEC response experience.
Nexalin Technology, Inc. filed an amended Form S-1/A with the SEC on October 8, 2026, updating its IPO registration. The company develops non-invasive neuromodulation devices. This amendment likely addresses SEC comments, updated financials, or underwriting terms—indicating active progress through the review process.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →